Novartis Advances Dermatology Portfolio With Cosentyx FDA Approval For Pediatric Patients

All NewsMarch 16, 2026

FDA approves Novartis’ Cosentyx for moderate to severe hidradenitis suppurativa in patients aged 12 and older, expanding treatment options.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent